Risultati per: Nuovi trattamenti nei linfomi non Hodgkin a cellule B

Circulation, Volume 148, Issue Suppl_1, Page A13023-A13023, November 6, 2023. Background:Non-Hodgkin lymphoma (NHL) survivors are at increased risks of cardiovascular disease related death (CVD) compared to the general population.Objective:This study sought to determine the longitudinal trends in mortality attributed to CVD with comorbid NHL by race, sex, and geographic location.Methods:We queried the Centers for Disease Control and Prevention’s Wide-Ranging Online Data for Epidemiologic Research database among patients aged 18 and above from 1999 to 2020. Patients were identified when the primary causes of death were ischemic heart diseases (ICD 10 I20-I25), cerebrovascular diseases (I60-I69), or hypertensive disease (I10-I15), and NHL (C82-C85) was a contributing cause of death. We calculated age-adjusted mortality rates (AAMRs) per 1,000,000 individuals and determined the trends over time by estimating the annual percent change using the Joinpoint regression program.Results:In the 22-year study period, a total of 22,778 CVD with comorbid NHL were identified. Overall, there was a significant decrease in annual trends for the AAMRs of CVD from 6.91 per 1,000,000 individuals in 1999 to 4.12 per 1,000,000 individuals in 2020 (p

Fondazione Tettamanti: ‘Più semplice e meno costoso delle Car-T’

Possibile ruolo contro Alzheimer e Parkinson

Studio, sono meno capaci di combattere il virus

Da ricercatori italiani e americani. Utile anche contro i tumori

Un brevetto Università Ca’ Foscari di Venezia e Cro di Aviano

This nonrandomized clinical trial investigates the addition of pembrolizumab to ifosfamide, carboplatin, and etoposide chemotherapy and evaluates the response rate of patients with relapsed or refractory Hodgkin lymphoma.

This systematic review with meta-analysis examines the regulatory oversight of the accelerated approval pathway and evidence generation for idelalisib during premarketing, postmarketing, and premarketing withdrawal periods.

Scoperta apre la strada a farmaci contro le neoplasie

This nested case-control study of 5-year Hodgkin lymphoma survivors explores dose-response associations of radiation therapy and procarbazine with colorectal cancer.

Uno biologico e sperimentale dal 15 aprile,l’altro psicoterapico

Lo studio dei ricercatori dell’Ifom di Milano e del Cnr-Igm di Pavia, appena pubblicato su Nature Cell Biology, dimostra che il coronavirus viola i sistemi delle cellule, ne danneggia il Dna e impedisce di ripararlo